Week in Review: The Age-Old Tale of Cost & Value

Week in Review: The Age-Old Tale of Cost & Value

08.01.14 | By

This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.

Hearing from groups and individuals from across the health care ecosystem is incredibly important to helping patients. As a result, we participated in the first Wall Street Journal tweet chat on the cost and value of innovation hosted by Ed Silverman of Pharmalot, with University of Southern California economics professor, Dana Goldman, co-hosting the chat. The diverse group offered a dynamic view on the cost/value topic, although the focus was on the fact that innovative treatments continue to provide value to our nation’s patients and economy. We hope to participate in future conversations like this one.

As we recognized World Hepatitis Day this week on Twitter and Facebook using the hashtag #WorldHeptatitisDay and #ThinkHepatitis, we were able to highlight the progress that we’ve made and the importance of including value in any conversation about cost. Thanks to groundbreaking research and development (R&D) for hepatitis patients, new hepatitis C treatments can now cure more than 90 percent of patients in just 12 weeks. Unfortunately, critics often focus on the short-term costs of these treatments rather than the long-term value of the cure, which can save patients thousands in out-of-pocket medical expenses and improve their quality of life. Help us keep the momentum around World Hepatitis Day going by educating yourself and others on the facts about hepatitis C treatments.

Ongoing discussions and collaborations in the U.S., and around the world, are vital to continuing the dialogue around patient health and the health of our economy. Check back next week for expert perspectives on important topics in health with a new Conversations question, and follow us on Twitter and Facebook for real-time updates on news from around the industry.


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context